Investment case
Humana Inc.
HUM · 26 developments mapped · last assessed 2026-09-18
Market Ontology has mapped 26 macro, policy, and market developments to Humana Inc. since 2026-09-05. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for HUM yet, so no modelled value is shown. The HUM valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run HUM on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Centene improves Medicare health benefit ratio to 89.5% amid footprint reset
Sector-wide sentiment improvement due to positive operational signals from a peer, suggesting broader industry trends.
· Moves sector profitability outlook, investor sentiment towards managed care
- Main threat
Centene posts Q2 adjusted EPS of $2.51 as Medicaid rolls face 8%-9% 2026 decline
Second-order effect; industry-wide Medicaid enrollment trends could impact HUM's Medicaid segment, though less dominant than Medicare.
· Moves medicaid membership growth rates, segment specific medical loss ratio (mlr)
- Open question
Centene Targets Medicare Advantage Margin Recovery as Q2 Medical Loss Ratio Hits 89.5%
As a major Medicare Advantage provider, Humana is directly exposed to the 'ongoing margin repricing across the managed care complex' and regulatory changes affecting MLR and profitability.
· Moves profitability outlook for medicare advantage, regulatory risk premium
What changed, by assumption
- 2026-09-12Centene improves Medicare health benefit ratio to 89.5% amid footprint reset
- 2026-09-12Centene Targets Medicare Advantage Margin Recovery as Q2 Medical Loss Ratio Hits 89.5%
- 2026-09-05UnitedHealth Medical Care Ratio Drops to 85.3%, Lifting 2026 EPS Consensus by 21%
- 2026-09-12Centene trims Medicare health benefits ratio to 89.5% aiming for 2027 breakeven
- 2026-09-05UnitedHealth Medical Care Ratio Drops to 85.3% as 2026 EPS Consensus Rises 21%
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-07-09 | Margin | Bearish | Identified by HHS OIG for high denial rates in post-acute prior authorization, increasing regulatory risk for MA-heavy insurers. | 0.75 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-18 | Centene Posts $2.51 Q2 EPS as Medical Cost Turnaround Offsets 8%-9% Medicaid Shrinkage | watch | 3-12m | 0.40 |
| 2026-09-18 | Centene posts $2.51 Q2 EPS as Medicaid rolls shrink 8%-9% in 2026 | watch | 3-12m | 0.40 |
| 2026-09-18 | Centene posts Q2 adjusted EPS of $2.51 amid 8%-9% projected Medicaid roll-off | watch | 3-12m | 0.30 |
| 2026-09-18 | Centene Delivers $2.51 Q2 EPS as Commercial Margins Offset 9% Medicaid Decline | watch | 1-3m | 0.30 |
| 2026-09-18 | Centene posts Q2 adjusted EPS of $2.51 as Medicaid rolls face 8%-9% 2026 decline | Bearish | 3-12m | 0.30 |
| 2026-09-18 | Centene Delivers Q2 Adjusted EPS of $2.51, Projects 8%-9% Medicaid Drop | watch | 3-12m | 0.40 |
| 2026-09-18 | Centene posts Q2 EPS turnaround to $2.51 as Medicaid rolls off 8% to 9% | watch | 3-12m | 0.30 |
| 2026-09-16 | Oscar Health, Inc. Raises Full Year 2026 Earnings Guidance | watch | 3-12m | 0.20 |
| 2026-09-16 | Centene Corporation Reaffirms Full Year 2026 EPS Guidance | watch | 1-3m | 0.30 |
| 2026-09-14 | Centene Restructures Medicare Advantage Footprint to Target 2027 Margin Breakeven | mixed | 3-12m | 0.40 |
| 2026-09-13 | Centene Improves Medicare HBR to 89.5% via Footprint Simplification | mixed | 3-12m | 0.40 |
| 2026-09-13 | Centene Targets 2027 Medicare Advantage Breakeven as Health Benefit Ratio Hits 89.5% | mixed | 3-12m | 0.30 |